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Abstract
Most psychotropic drugs used in the treatment of children and adolescents are applied "off label"
with a direct risk of under- or overdosing and a delayed risk of long-term side effects. The selection
of doses in paediatric psychiatric patients requires a consideration of pharmacokinetic parameters
and the development of central nervous system, and warrants specific studies in children and
adolescents. Because these are lacking for most of the psychotropic drugs applied in the Child and
Adolescent and Psychiatry, therapeutic drug monitoring (TDM) is a valid tool to optimise
pharmacotherapy and to enable to adjust the dosage of drugs according to the characteristics of
the individual patient. Multi-centre TDM studies enable the identification of age- and development-
dependent therapeutic ranges of blood concentrations and facilitate a highly qualified standardized
documentation in the child and adolescent health care system. In addition, they will provide data
for future research on psychopharmacological treatment in children and adolescents, as a baseline
for example for clinically relevant interactions with various co-medications. Therefore, a German-
Austrian-Swiss "Competence Network on Therapeutic Drug Monitoring in Child and Adolescent
Psychiatry" was founded [1] introducing a comprehensive internet data base for the collection of
demographic, safety and efficacy data as well as blood concentrations of psychotropic drugs in
children and adolescents.
Introduction
Epidemiological data show remarkable differences in pre-
scribing patterns and use of medication in child and adoles-
cent psychiatry between the US and Europe, but also
among European countries [2,3]. Prevalence of the use of
antipsychotic and antidepressant medications is higher in
the U.S. and prescribing patterns of substance classes differ.
For example, the annual prevalence of antidepressant and
stimulant medication was three times greater in the US
than in the Netherlands or Germany, that of antipsychotics
was 1,5–2,2 times greater, respectively [4] In the U.S. sec-
ond generation antipsychotics (66% of total antipsychotic
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prescriptions versus 48% in the Netherlands versus 5% in
Germany) and selective serotonin reuptake inhibitors
(SSRIs) are the most used drugs for the respected indica-
tions, in Germany first generation antipsychotics, herbal
medicines (esp. St John's wort) and tricyclic antidepres-
sants (73% of total antidepressant prescriptions in Ger-
many versus 48% in the Netherlands and 15% only in the
U.S.) are the predominantly prescribed drugs [4]. Anyhow
there is a considerable amount of off-label prescription of
psychotropic medication in all western countries for the
treatment of psychiatric disorders in children and adoles-
cents. This results in a major ethical and safety problem
because usual mechanisms of data collection fail. Therefore
there is an increased need of generating reliable reports on
individual response and especially on side effects in chil-
dren and adolescents. For this reason in the U.S. large net-
works like the CAPTN network (Principle investigator: John
March) have been created to collect so-called real life data
from thousands of sites throughout the U.S. taking account
of co-medication, augmentation and individual side
effects. But within these networks only standardized reports
are collected. There is no biological measure of serum
blood-levels of the prescribed drugs nor are there any data
on pharmacogenetics. In central Europe safety interest and
the striving for quality assurance in medical care allows the
analysis of blood samples in this context of off-label medi-
cation. Therefore it seemed to be evident that a network
using standardized side effect reports comparable to the
CAPTN study and collecting biological data should be built
up in Germany or in Europe. In 2007/2008 we concluded
a contract with Dr. March's group on the use and transla-
tion of the PAERS scale and other instruments used in the
CAPTN network. At the same time we established a compu-
ter based platform for a German multi-centre observational
safety-oriented study.
This paper briefly reviews the current situation in child
and adolescent psychopharmacotherapy. Then it is dis-
cussed what is known about the developmental differ-
ences in physiological factors that influence the therapy
with psychotropic drugs in child and adolescents. Finally,
therapeutic drug monitoring (TDM), an appropriate tool
for the improvement of dosing and drug safety, and the
German-Austrian-Swiss "Competence Network on TDM
in Child and Adolescent Psychiatry" [1] that uses a com-
prehensive internet data base for the collection of demo-
graphic, safety and efficacy data as well as serum levels of
psychotropic drugs in children and adolescents, is
described.
Safety of psychotropic medications in children: A 
developmental issue
Current situation in the psychopharmacology of child and 
adolescents in Europe
A widespread use of off-label medication in paediatrics, as
well as in child and adolescent psychiatry characterizes
the pharmacoepidemiological situation in Europe [5-7].
This situation is ethically problematic[8,9]:
￿ Most psychotropic drugs used in children and ado-
lescents have neither been developed nor assessed in
these age groups.
￿ Very few psychotropic drugs have a paediatric indi-
cation and defined posology (for example ampheta-
mine und methylphenidate in the treatment of
ADHD).
￿ As children and adolescents are subject to many of
the same diseases as adults, and consequently often
treated with the same drugs, prescribing drugs "off
label" can place the paediatric population at a direct
risk of under- or overdosing and a delayed risk of long-
term side effects.
The deficiencies of paediatric drug development proce-
dures and reasons for a lack of labelled drugs are well
known and have been published elsewhere (e.g. [10,11]).
As a result of missing data by randomized controlled trials
in minors no second generation antipsychotics is labelled
for minors in Germany, besides risperidone, which is only
labelled for behavioural use, but not for the use in psycho-
sis. Clozapine is labelled for minors of 16 years and older,
but only as a treatment strategy in third line. The lack of
evidence for the use of most SSRIs in minors implies the
need for further studies on the treatment of Major Depres-
sive Disorders in minors [12]. At present only some prep-
arations of fluoxetine are licensed for the use of children
older than eight years. Concerning SSRIs, Safer and Zito
found that safety aspects of drug treatment in minors are
related specifically to age groups [13,14] and pointed out
the need of studies about Major Depressive Disorders in
naturalistic designs to compare efficacy, effectiveness and
safety of several treatment strategies under realistic condi-
tions. Moreover, differences between the U.S. and Europe
in the indicated prevalence of some disorders, e.g bipolar
disorder, lead to essential disparate treatment strategies
[15,16].
Research on medications for minors in Europe
Whereas in the U.S. publicly funded clinical trials, driven
by some legislation, have been conducted in the last years
with high impact on clinical practise (e.g the MTA study,
the TADS trial), in Europe clinical trials are predomi-
nantly driven by industry [17]. Most data about second
generation antipsychotics in minors were collected by
Research Units on Pediatric Psychopharmacology, driven
by the "pediatric rule" [18]. Investigator initiated trials are
rare in Europe [19]. A new European Directive was imple-
mented in summer of 2007 to increase drug safety also for
minors. Thus, clinical trials in minors shall be pushed
with incentives, based on regulations similar to the U.S.Child and Adolescent Psychiatry and Mental Health 2009, 3:14 http://www.capmh.com/content/3/1/14
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with a sort of "stick and carrot" policy for pharmaceutical
industry (e.g. extension of patents) [20]. Especially the
collection of long-term safety data was one of the major
aims of this directive, since most safety investigations of
randomized controlled trials refer to short follow-up
durations only.
Conditions of health systems
In most European countries the health care system shows
substantial differences from the U.S. Health insurance and
access to care is available nearly for all people by state-run
health insurance companies. Whereas this high standard
is provided, on the other hand the safety aspects of drug
treatment for a population with special need for protec-
tion (like minors with psychiatric disorders) are
neglected. Collecting safety data by health insurances and
networks for monitoring and reporting of pharmacologi-
cal safety data and side effects could be easily imple-
mented, but this did not happen yet. Especially for minors
with differences in physiological factors that influence the
pharmacology of drugs, a safety system in standard treat-
ment would help to solve the black box of safety and of
unknown relationship between the dosage and actions of
drugs (e.g. effectiveness and side effects). At present, in
Europe the ethically problematic situation of lower stand-
ards of drug-safety for children continues, due the lack of
paediatric pharmacokinetic and -dynamic trials and non-
existing data. The European Agency for the Evaluation of
Medicinal Products (EMEA) is responsible for the imple-
mentation of the European Risk Management Strategy
(ERMS). For the enhancement of safety surveillance, the
introduction of a special EUDRA (European Union Drug
Regulatory Authorities) Vigilance Datawarehouse and
Analysis System is planned. Besides spontaneous report-
ing of adverse event systems, a network of centres for
pharmacoepidemiology and pharmacovigilance is war-
ranted in order to facilitate multi-centre studies or to
authorize safety topics [8].
Developmental psychopharmacology
More than 100 years ago Dr. Abraham Jacobi, the father of
American paediatrics, recognised the importance of and
need for age-appropriate pharmacotherapy when he
wrote, "Pediatrics does not deal with miniature men and
women, with reduced doses and the same class of disease
in smaller bodies, but ... has its own independent range
and horizon (see [21]) The recognition that developmen-
tal changes profoundly affect the responses to medica-
tions (both efficacy and side effects) produced a need for
age-dependent adjustment in doses. However, the selec-
tion of doses in paediatric patients requires a considera-
tion of pharmacokinetic parameters, and warrants specific
studies in children and adolescents (See Table 1).
Ontogenesis of pharmacokinetics
As summarized in Table 1, developmental changes in
physiology produce many of the age-associated changes
in the absorption, distribution, metabolism, and excre-
tion of psychotropic drugs following oral administration
(most drugs are administered orally to children and ado-
lescents) that result in altered pharmacokinetics and thus
serve as the determinants of age-specific dose require-
ments. However, no systematic studies were carried out to
show how each of these factors is changed over lifetime
and whether there are gender dependent changes. These
developmental changes in physiology have – dependent
on the psychotropic drug administered – different effects
on concentrations in the blood (Table 2) and most likely
also at the target structures in the central nervous system
(CNS). Therefore, the approach to extrapolate age-specific
dosing regimes from adult data has limited value and the
selection of doses in paediatric patients requires a consid-
eration of pharmacokinetic parameters. It has been
hypothesized that inaccurate dosing parameters were the
reason for the negative outcome of the studies of antide-
pressants in paediatric patients with Major Depressive
Disorder [22] (see Table 2).
Table 1: Age-dependent factors that influence the pharmacokinetics in children and adolescents
Pharmacokinetic parameter Influencing factors
Absorption Gastrointestinal function 
(for example gastric emptying and intestinal motility; hydrochloric acid production, bile acid 
secretion, intestinal and body length)
Distribution Body composition 
(for example extra-cellular and total-body water space, volume of distribution, changes in 
the composition and amount of circulating plasma proteins, body fat)
Regional blood flow
Organ perfusion
Permeability of cell membranes
Acid-base balance
Passive diffusion of drugs into the central nervous system
Metabolism Metabolic capacity 
(for example liver size, activity of drug-metabolising phase I and II enzymes such as P-450 
cytochromes and glucuronosyltransferase)
Excretion Renal function
(modified according to [21,42]).Child and Adolescent Psychiatry and Mental Health 2009, 3:14 http://www.capmh.com/content/3/1/14
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Ontogenesis of pharmacodynamics
Although it is generally accepted that development can alter
the action of and response to a drug, little information exists
about the effect of human ontogenesis on interactions
between psychoactive drugs and biological target structures
(i.e. the pharmacodynamics) and the consequence of these
interactions (i.e. efficacy and side effects). Although, cell
birth, neuronal differentiation and migration of neurons to
target areas are almost complete within the first few years of
life in humans, there is a lifelong change in the synaptogen-
esis and synapse elimination with changes in the density of
neurotransmitter receptors, sensitivity of signal transduction
pathways, activity of neurotransmitter metabolising
enzymes and density of neurotransmitter re-uptake trans-
porters. Post-mortem studies and high-resolution structural
magnetic resonance imaging longitudinal studies demon-
strated non-linear region- and neurotransmitter-specific
changes. For example, Giedd et al. [23] found age- and sex-
specific changes in the cortical gray matter, with develop-
mental curves for the frontal and parietal lobe peaking at
about age 12 and for the temporal lobe at about age 16,
whereas cortical gray matter continued to increase in the
occipital lobe through age 20. The frontal and parietal gray
matter peaks approximately one year earlier in females, cor-
responding with the earlier age of onset of puberty. In
human post-mortem studies is has been shown that there is
a transient elevation of both the dopamine D1- and D2-
receptor density (the main therapeutic target of antipsychot-
ics in the brain) in the early childhood; after about 2–5 years
there is a rapid decline, and after ten years D1 and D2 receptor
density decreases at about 3.2 and 2.2 percent per decade,
respectively [24]. In addition, it has been reported that there
is an age-dependent development of human neuromelanin.
This dark-coloured pigment is formed in the dopamine neu-
rons of the human midbrain and interacts with a variety of
potentially damaging molecules such as iron but also with
neuroleptics [25]. Neuromelanin was not present at birth
and initiation of pigmentation began at approximately three
years of age, followed by a period of increasing prigment
granule number and increasing pigment granule colouration
until age 20 [25].
The ontogenesis of the CNS has an influence on the inter-
action of a psychotropic drug with biological structures in
the CNS (e.g. neurotransmitter metabolism, neurotrans-
mitter receptors, neurotransmitter transporters, signal
transduction) and the resulting therapeutic effect. These
changes in the ontogenesis of pharmacodynamics indi-
cate that there is a difference in the relationship between
the blood concentration of a psychotropic drug and ther-
apeutic response to a psychotropic drug in children, ado-
lescents and adults. Indeed, we have shown by performing
TDM that more than 50% of the quetiapine trough serum
concentrations were not within the therapeutic range rec-
ommended for adults [26]: 40.8% of the determined val-
ues were below and 24.5% above the therapeutic range
(70–170 ng/ml) recommended for adults. Interestingly,
none of the patients had severe side effects.
Pharmacogenetic aspects
Genetic variability influences drug effects from absorption
of the drug until its complete elimination [27]. Genetic
variability exists both at the pharmacokinetic and phar-
macodynamic side of drug action. Many enzymes
involved in drug metabolism carry genetic variants (poly-
morphisms) which can decrease enzyme activity or even
lead to complete deficiency [28]. Genetic variants in drug
targets such as receptor molecules or intracellular struc-
tures of signal transduction and gene regulation directly
and indirectly influence drug response.
Genetic polymorphisms lead to different phenotypes of drug
metabolizers which generally have been referred as "poor
metabolizers" (carrying two alleles predicting a low or no
enzyme activity), "intermediate metabolizers" (being heter-
ozygous carriers of one inactive allele or of two alleles with
reduced activity), and "extensive metabolizers" (carrying two
active alleles) and, for some enzymes, "ultra-rapid metabo-
lizers" (revealing a very high enzyme activity which is genet-
ically caused by gene duplication, so far only found for
CYP2D6 and CYP2A6; [29]. The phenotypes reflecting the
actual enzyme activity still show high inter-individual varia-
tion especially within the intermediate and extensive metab-
olizer groups. Thus, genetic prediction of enzyme activity is
best possible for the poor and ultra-rapid genotypes, but
poor or ultra-rapid metabolizing activity can also be caused
by enzyme inhibitors or inducers [30].
The prevalence of the different types of metabolizers var-
ies a lot between ethnic groups [31]. For CYP2D6 which
Table 2: Effects of developmental factors on the pharmacokinetics and the efficacy of psychotropic drugs
Developmental factor Pharmacokinetic effects Clinical effects
Liver size and activity of CYP450 enzymes ↑ Increased drug metabolism Insufficient drug efficacy
Percentage of body fat ↓ Reduced storage of lipophilic drugs
Glomerular filtration rate ↑ Faster urinary excretion
Protein binding ↓ Increased drug availability Increased risk of side effects
Gastro-intestinal resorption ↑ Increased drug availability both in peripheral organs and the brain
CYP450, P-450 cytochrome
↑, Increase compared to adults; ↓, Decrease compared to adultsChild and Adolescent Psychiatry and Mental Health 2009, 3:14 http://www.capmh.com/content/3/1/14
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catalyses the hydroxylation of many tricyclic antidepres-
sants and other psychotropic drugs, 5 to 8% poor metab-
olizers and 1 to 10% ultra-rapid metabolizers have been
found in Caucasians. In Ethiopia and some Arab coun-
tries, even up to 30% are carriers of the CYP2D6 gene
duplication [32]. CYP2C19 polymorphisms in Caucasian
populations seem to be less important although several,
mainly tricyclic, antidepressants are metabolized by this
enzyme. In Asian populations, however, about 20% of the
population are CYP2C19 poor metabolizers [33].
In young patients, especially in smaller children, pharma-
cogenetics might gain a special importance since the
enzyme activity changes over the time especially in early
development. A fatal developmental-pharmacogenetic
interaction has recently been reported for codeine in a
mother who genetically was an ultra-rapid metabolizer of
codeine to morphine and breasted a neonate who got poi-
soned from morphine because of lack of glucuronidation
activity which is common in neonates [34]. Thus, phar-
macogenetics might gain special importance in children
when enzyme activities differ from those in adults.
Pharmacogenetic testing can be a valuable tool in psy-
chopharmacotherapy if genetic testing can be performed
with a reasonable effort. Depending on the particular
CYP450 enzyme, different genotyping methods are avail-
able and are offered by commercial labs, university sites or
centres doing TDM. TDM and pharmacogenetic tests can
advantageously be combined with TDM that to a certain
extent can be considered as a phenotyping procedure.
Pharmacogenetic tests might be indicated in the case of
unusual plasma concentration to dose relations or when
the ratio of parent substance to metabolite is distorted.
Genotyping is considered as a "trait marker" and its result
does not depend on environmental factors, meaning that
it has only to be performed once in a person's lifetime. In
general, a DNA probe is extracted from a non-centrifuged
whole blood sample, but material such as buccal swabs or
saliva samples may also serve. Genotyping tests are rou-
tinely available for CYP2D6 and CYP2C19, and research-
based laboratories might offer further gene tests. Geneti-
cally caused variability in drug metabolism can be over-
come by genotype-based dose adjustments. These dose
adjustments are calculated according to the principles of
bioequivalence under consideration of special circum-
stances like linearity of pharmacokinetics, activity of
metabolites, and dose range of the underlying studies.
Methods for extracting dose adjustments from pharma-
cokinetic data in dependence of genotypes have been
developed and published elsewhere [35-37].
Pharmacogenetic testing is combined to TDM in adult
drug therapy mostly for explaining abnormalities in drug
metabolism, side effects, and some times therapeutic fail-
ure [38]. In children and adolescents, specific changes in
enzyme activity during development lead to specific sus-
ceptibility of this patients for adverse drug effects in gen-
eral, and the combination of specific developmental
changes in metabolic capacity with pharmacogenetic pro-
files might lead to side effects or poor outcome specifically
in those subgroups of patients. One study looking at new-
borns exposed to antidepressant treatment with SSRIs
revealed that those with a low-activity genotype of the
serotonin transporter had more toxicity through maternal
drug therapy than those with the high-activity genotype
which was reflected in lower birth weight and lower per-
formance after birth [39]. One case of a newborn infant
dying from morphine intoxication has been described due
to the ultrarapid metabolizer state of the mother who
metabolized codeine to morphine, and due to the low
glucuronidation capacity of the infant, it got intoxicated
with morphine [34]. Indeed, these are data from new-
borns who certainly are more susceptible to drug toxicity
but we know that children and adolescents differ from
adults in many aspects of drug metabolism. Thus, these
patients are already at risk for over-dosing or under-dos-
ing since we do not know their exact metabolic underpin-
nings. Genotyping for pharmacogenetic polymorphisms
will provide additional information on the individual
drug metabolizing capacity, and sometimes also informa-
tion on drug efficacy, and if performed in combination
with TDM, we expect further insights into the specific
requirements for drug therapy of these patients.
Aims of Therapeutic Drug Monitoring (TDM)
TDM comprises the measurement of plasma or serum
levels and the documentation of both the clinical effi-
cacy and side effects (Baumann et al., 2004). TDM is a
valid tool to optimise pharmacotherapy. It enables the
clinician to adjust the dosage of drugs according to the
characteristics of the individual patient. The interdisci-
plinary TDM expert group of the Society of Neuropsy-
chopharmacology and Pharmacopsychiatry (AGNP,
[40]) analysed published data on 65 psychopharmaca
and defined therapeutic ranges of plasma levels [38].
Moreover, they constituted a recommendation system
for the implementation of TDM of 5 levels, indicating
TDM most urgently for the treatment with lithium, but
also for amitriptyline, clomipramine, clozapine, flu-
phenazine, haloperidole, imipramine, nortriptyline and
olanzapine. For augmentation strategies or comedica-
tion in general TDM also provides support in dosage
finding and prevention of toxic or unwanted side effects
[38,41,42]. Other indications for TDM include the con-
trol of compliance, the lack of dosage correlated medica-
tion efficacy and the incidence of severe side effects.
Because empirical data on drugs with psychotic drugs in
children and adolescents are limited and most are not
approved for this young age group, the administration of
psychopharmaca in children and adolescents is a general
indication for TDM [38,43].Child and Adolescent Psychiatry and Mental Health 2009, 3:14 http://www.capmh.com/content/3/1/14
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Description of the multi-centre drug monitoring 
data base
Because for many of the psychotropic drugs applied in the
Child and Adolescent and Psychiatry data on pharmacok-
inetics, efficacy and side effects are lacking, and many psy-
chiatric disorders (with exception of ADHD) have a low
incidence, we established a "Competence Network on
Therapeutic Drug Monitoring in Child and Adolescent
Psychiatry" in December 2007 [1], including 12 Depart-
ments of Child and Adolescent Psychiatry in Germany,
Austria and Switzerland. The Network uses a multi-centre
TDM system including both standardized measurements
of blood concentrations of psychotropic drugs and the
documentation of efficacy and side effects of the medica-
tion. For practical reasons, the use of an internet data base
was chosen in order to save and to systematically structure
the huge data amounts that have to be expected. Such a
data-based documentation will simplify final evaluation
procedures. Furthermore, individuals with abnormal
blood levels on the one hand or low drug efficacy or
severe side effects, respectively, despite of normal plasma
levels on the other hand, could be detected easily and e.g.
transferred to further genetic analyses.
Conditions
As described above, health care systems in Western Europe
provide an access to care for nearly all people. Regular
blood examinations that are already done as a matter of
routine in clinical visits of the patients could increase data
about concentrations, dose-efficacy and side-effects with-
out bothering the patient by additional visits and enrol-
ment in studies. This data, collected with the first aim of the
individual benefit for the patient, would at the same time
increase the potential benefit for this group of patients by
systematically generating a database for safety parameters.
The non-evidence based prescribing practise with non-sys-
tematically assessment of prescriptions, of blood levels and
of effects as well as of side effects is replaced by a more evi-
dence-based treatment with medication.
Technical characteristics of the database
The data are recorded with the medical database system
SecuTrial®. SecuTrial® is a strictly internet-based system in
connection to a relational Oracle database, made for col-
lecting pseudonymised medical data. SecuTrial® was orig-
inally developed for the Competence Network on
Parkinson's disease (CNP) and adapted by the Compe-
tence Networks Dementia, Congenital Heart Defects,
Creutzfeld Jakob Disease, Restless Legs Syndrome, Brain-
Net, European Networks-of-excellence EuroPa, EU Brain-
Net, the Coordination Centre for clinical trials, KKS in the
last years and for clinical trials of several pharmaceutical
companies. The CIO of the Competence Network on Par-
kinson's disease with its large experience in long-time
medical registers functions as the CIO for the "Compe-
tence Network on Therapeutic Drug Monitoring in Child
and Adolescent Psychiatry" as well and takes care for the
register data quality according to strong scientific guide-
lines. SecuTrial® contains functions for data input about
forms, reports, statistics, inspection, export and data eval-
uation. The complete dataset is organised in form fami-
lies. Medical data can be collected from as many research
groups and as many examinations as wanted over a time
line of follow-ups, presented as case history (Additional
file 1, fig. 1a and fig. 1b).
To fulfil the legal requirements for data safety and protec-
tion laws of the included European countries all persons
authorized for data input and view are part of a sophisti-
cated user, privilege and role system. Patients as well as
authorized persons are relocated to enclosed centres (e.g.
hospitals). Due to protection of data privacy the clinical
data are labelled only with a patient identification
number (pseudonym) and clinical investigators can only
access clinical data of their own centre. Moreover the right
and role system can give authorized user access to single,
some or all data forms with different view privileges. The
data forms of the database system react interactive with
these rights and roles: a user with a role, not authorized
for a certain data form, will not be able to access.
This flexibility is used for the important interaction with
the central labs. Authorized persons of the centre "central
lab" may access the medication data form of all patients
of all centres to enter serum levels using a second patient
identification number (labID), but may not revise any
other data forms.
In addition each data change is noted together with user
name, date and time in the audit trail.
With its right and role system SecuTrial® is certified to
meet all requirements according to GCP, AMG, EMEA and
FDA (21 CFR Part 11). Furthermore the system's security
concept (secure hosting, firewall system, daily database
and log file backups) possesses the TÜV-IT certificate
"trusted site".
Design of the platform
The platform is used for routine TDM in all cases of ther-
apy with psychotropic drugs. For the pilot period, the
study evaluation focuses on atypical antipsychotics and
modern antidepressants, especially SSRIs. Every patient
treated with psychotropic drugs is enrolled. Ethical com-
mittees did approve the study design stating that TDM as
a part of routine procedures in order to optimize dosage
finding and prevention of side effects even needs no
informed consent. However, for data safety reasons, forms
of informed consent on data collection and data analysis
is provided nonetheless.Child and Adolescent Psychiatry and Mental Health 2009, 3:14 http://www.capmh.com/content/3/1/14
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Due to standardized operational procedures, 10–12 hours
after the last dose, blood samples (7.5 mL) are collected in
the morning at steady state. Analyses are performed in
centralized labs providing standardized procedures by
high-performance liquid chromatography (HPLC) and
ultraviolet (UV) detection according to the guidelines of
the AGNP TDM expert group.
The database, using codes for pseudonymization, com-
prises demographic data (age, gender, body weight,
height, BMI, diagnose, medication given, dosage, begin-
ning of therapy with this medication, pattern of titration
before, use of nicotine or alcohol or other interfering sub-
stances, compliance) and validated tools on the general
efficacy of medication and the patient's global function-
ing as well as the documentation of side effects. Specific
rating scales for schizophrenia and depressive disorders
are implemented already, further instruments might be
included depending from the scientific aims. The Pediat-
ric Adverse Events Rating Scale (PAERS), developed for the
Child and Adolescent Psychiatry Trials Network (CAPTN;
[44]), is provided for adverse events. Rater trainings are
implemented within initiation meetings of participating
centres and are repeated regularly when additional clinical
investigators are enrolled to warrant a highly qualified
standardized documentation. In addition, the principal
investigators of each centre are obliged to train their assist-
ants.
For every patient enrolled, a baseline visit is performed
comprising the demographic items and psychometric
tools as described above. As soon as the new medication
is started, follow-up visits including serum level analyses
report on the efficacy and safety of the psychopharmaco-
logical treatment regarding potential interfering aspects.
TDM is performed until adequate remission of the target
symptom of medication.
Perspectives
Adequate dosing in paediatric psychiatric patients
requires a consideration of pharmacokinetic parameters
and the development of the CNS, and warrants specific
studies in children and adolescents. Because these data are
lacking for most of the psychotropic drugs applied in the
Child and Adolescent and Psychiatry, TDM is a valid tool
to optimise drug therapy and to enable to adjust the dos-
age of drugs according to the characteristics of the individ-
ual patient. Multi-centre TDM studies providing large
patient samples, standardized measurements of blood
concentrations of psychotropic drugs, baseline and fol-
low-up assessment of psychopathology and the documen-
tation of side effects enable the identification of age- and
development-dependent therapeutic ranges of blood con-
centrations, thus facilitating dosage finding, improving
efficacy and minimizing the risk of side effects. Pharma-
cokinetic abnormalities in individual patients could be
further investigated by the classification of pharmacoge-
netic subtypes. Moreover, multi-centre standardized TDM
documentation will provide data for future research on
psychopharmacological treatment in children and adoles-
cents, as a baseline, for example, for clinically relevant
interactions with various co-medications. A TDM data
base therefore will not only increase the limited knowl-
edge on pharmacokinetic and pharmacodynamic condi-
tions in minors but also provide individual benefits for
the patients participating in terms of individualized ther-
apy with psychotropic drugs. Moreover, it facilitates a
highly qualified, standardized documentation in the child
and adolescent health care system.
From a scientific perspective, the TDM database can be
regarded as a basic tool for the implementation of multi-
centre clinical trials and observational studies since the
body of data collection can be extended or changed flexi-
bly, depending on the aims of the respective study. Secu-
Trial offers monitoring and query systems, data entry
complete functions, source data verification functions and
AE/SAE forms thus providing any technical equipment
that is required for trial support. Additional investigations
might either be set-up independently from the original
data base or be implemented within the existing TDM reg-
ister. Therefore, on the one hand, it allows the restriction
on basic data only for centres that primarily want to focus
on essential clinical data documentation, and it enables
scientific trials with specifically increased data collections
on the other hand.
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